

**CUMULATIVE SENSITIVITY REPORT
PRMCE INPATIENT 2021**

Mena Senecal, PharmD, BCIDP
Antimicrobial Stewardship Pharmacist
425-261-3530

Helen Kim, SM(ASCP), MBA
Microbiology Supervisor
425-261-3756

Kirstine Oh, MD
Laboratory Medical Director
425-261-3678

GRAM POSITIVE ANTIBIOGRAM	ampicillin	ampicillin/subactam	cefazolin	ceftioxone	clindamycin	gentamicin synergy	levofloxacin	linezolid	nitrofurantoin	oxacillin	penicillin	sulfamethoxazole/trimethoprim	tetracycline	vancomycin
enterococcus faecalis (360)	99.7					83	89	100	99		99			100
enterococcus faecium (32)	45					100	45	100	33		45			63
staphylococcus aureus (1032)		62	62		79		61	100	99	62		87	94	100
MRSA (396)		0	0		76		20	100	99	0		73	92	100
MSSA (636)		100	100		81		86	100	100	100		96	95	100
staphylococcus coagulase negative (107)		41	41		62		75	100	100	41		72		100
streptococcus pneumoniae (26)				100	88		100							100

GRAM NEGATIVE ANTIBIOGRAM	amoxicillin/clavulanate	ampicillin	ampicillin/subactam	cefazolin	cefepime	ceftazidime	ceftioxone	ciprofloxacin	ertapenem	gentamicin	imipenem	levofloxacin	meropenem	nitrofurantoin	piperacillin/tazobactam	tobramycin	sulfamethoxazole/trimethoprim
acinetobacter spp (46) ^{^A}			95		83	72	33	78		93	93	86			81	98	98
citrobacter freundii (51)					98	73	73	92	100	96	100	92			80	98	82
enterobacter cloacae (114)					97	76	75	96	98	99	98	97		40	79	98	96
escherichia coli (1165) [^]	85		66	85	91	90	90	82	99.8	92		82		97	98	92	79
haemophilus influenzae (27)		81															
klebsiella (enterobacter) aerogenes (40) ^{^~}					97	73	75	98	98	100	97	98		18	63	100	100
klebsiella oxytoca (114)	95		66	68	96	96	96	99	100	98		98		87	97	97	97
klebsiella pneumoniae (295)	96		83	88	90	89	89	96	99	98		97		30	98	97	86
morganella morganii (50) ^{^~}					100	84	96	90	100	90	91	96			98	92	86
proteus mirabilis (215) ^{^~}	99		85	67	96	96	96	75	100	90	93	78			99	89	79
pseudomonas aeruginosa (298) ^{^A}					93	91		89		96	94	86	80		92	100	100
serratia spp (84) [^]					100	100	98	94	100	100		94				85	100
stentrophomonas maltophilia (52)												94					96

This year's antibiogram is aligned with CLSI M39-A4 guideline for antibiogram development recommendations: 1) A minimum of 30 isolates. Please exercise discretion when interpreting the susceptibility of organisms with < 30 isolates. 2) Any repeated isolate from the same patient within the 90 day period are excluded in the antibiogram report. Any deviations are noted below by the corresponding footnotes.

^{*} Piperacillin/tazobactam was not routinely tested by Sacred Heart core microbiology lab. The data available from PRMCE microbiology lab was greater than 30 therefore reported in the antibiogram.

[^] Meropenem was not routinely tested by PRMCE microbiology lab. The data available from Sacred Heart core microbiology lab is below the 30 threshold therefore is not reported in the antibiogram.

[^] The data for escherichia coli only includes results performed by PRMCE microbiology lab and does not include patients who had repeat escherichia coli within a 90 day period due to inability to validate the susceptibility report from Sacred Heart core microbiology lab (missing approximately 6-8 weeks of data).

[~] Imipenem was not tested by Sacred Heart Core Microbiology lab. The data available from PRMCE microbiology was greater than 30 therefore reported in the antibiogram.

^{^A} Meropenem was not routinely tested by PRMCE microbiology but was by Sacred Heart core microbiology lab. N for meropenem data is 50 therefore was included in the antibiogram.

[^] Sulfamethoxazole/trimethoprim was not routinely tested by Sacred Heart core microbiology lab but was by PRMCE microbiology. The data available from PRMCE microbiology was greater than 30 therefore reported in the antibiogram.